A new option for patients with treatment-resistant migraine

Monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway are a substantial advance in the prevention of migraine. In The Lancet Neurology, Messoud Ashina and colleagues report the results of DELIVER, a randomised, multi-arm, double-blind, placebo-controlled trial of eptinezumab for the prevention of migraine.1 The study included participants with two-to-four migraine preventive treatment failures, similar to participants in the LIBERTY (erenumab),2 FOCUS (fremanezumab),3 and CONQUER (galcanezumab)4 trials.